Q2 2020 Rockwell Medical Inc Earnings Call
The bike and welcome to the Rockwell medical 2022nd quarter results call. At this time all participants are in listen only mode. After the speakers presentation. There will be a question and answer session to ask a question. During this session you lead to press Star one on your telephone as a reminder, today's program is being recorded I would now like to do so.
Your host for today's program Claudius dicing or.
Mr Relations. Please go ahead.
Welcome to Rockwell Medicals second quarter 2020 earnings results call.
This is Claudia I fear of Argo partners, the Investor Relations representative for Rockwell medical.
Joining me from Russell Medical on today's call are Dr., Russell Ellison, President and Chief Executive Officer, Tim Coal Vice President of marketing.
And Paul Mcgarry, Vice President corporate controller, and principal accounting officer.
Dr., Marc Hoffman, Chief Medical Officer, who will also be joining us for today's on the line.
Before we begin I wanted to know that certain matters. The oldest sets may constitute forward looking statements within the meaning of the federal securities laws, including but not limited to Rockwell medicals intention to commercialize triferic dialysate interfered ask you.
Words, such as me, Mike will should believe expect into seat estimate continue could potential predict forecast for Jack plan intend or similar expressions for statements regarding intent belief or current expectations are forward looking state.
Yes.
Well Rockwell medical believes these forward looking statements are reasonable undue reliance should not be placed on any such forward looking statements. What's your based on information available to us on the date of this really.
And which are subject to inherent uncertainty.
These forward looking statements are based upon current estimates and assumptions are sure subject to various risks and uncertainties, including without limitation those set forth in Rockwell medicals I see see filing.
Many of which are beyond our control and subject to change actual results could be materially different.
Accordingly, you should not place undue reliance on these forward looking statements.
Rockwell medical expressly disclaims any obligation to update or alter alter any statements whether as a result of new information future events or otherwise except as required by law.
This conference call can be accessed on Rockwell Medicals Investor Relations Web page. This call is being recorded on August 10th 2020 for audio rebroadcast and can also be access on the same web page.
At this time I would like to turn the conference call are very rough on Medical's, Chief Executive Officer, Dr. Russell Allison Russell.
Thank you Claudia.
Good afternoon, everyone and thank you for your time today.
On today's call, we will address our commitment to making the Dallas is community, particularly in light of to cope with 19 pandemic.
The progress.
First why they should never first approved products plus the dialysate, including updated hospitalization data from our ongoing real world data retrospective analysis.
Progress on our preparations for the launch of our secondary.
Right Doug Avenue.
Leading opportunities for new indication for MPC platform.
Other pertinent corporate update and a review of our financials.
And then we'll open it up the acuity.
I've said before and I'd like to take this opportunity to see again that I'm, particularly excited about the potentially transformational attribute of our very powerful it's a trade for PC technology platform.
Hi, Jerry because the first commercial product for Myrisk PC platform. Unlike any other on public on the market today.
Delivers 100% immediately Bioavailable Asian, I'm impeded by inflammation.
Virtue of this mechanism of action I believe RFP platform has potential to deliver meaningful clinical embalming cooked and all these.
Patients in health care providers.
Thereby transforming the way our deficiencies are managed across the globe.
Walter.
My charges CEO actualize, the potential of RFP technology for patients and for shareholders.
The opportunity in two areas.
The first is the ability to transform the way I mean is that it's pretty much dialysis patients.
Second is through the development of the hurt our policy titrate molecule or a B C.
Treat other medical conditions with unmet clinical needs.
To help accelerate the adoption of Triferic and hemo dialysis setting.
Continued to build and leverage the medical capability at Rockwell Medicals establishes because decision, making in dialysis is underpinned by medical scientific and Pharmacoeconomic data.
This him.
Continue to generate additional clinical in pharmacoeconomic data, including data from a real world data program I.
I'm pleased to be sharing some additional information from that program about the impact to try to all hospitalizations on our call today.
Also relevant to be modalities setting is the anticipated introduction of 58 shy in the next 12 to 24 month.
Which are expected to change the management of the media in the Dallas, We plan to strategically positions library alongside the appeared tries to provide a reliable and physiologic treatment of anemia.
Well spacing.
We anticipate that the PXI innovations, which we expect to come to market next year present, an important opportunity for triferic.
Regarding the development BSP platform to treat other medical conditions with unmet clinical need and it sounds good potential value creation for the company I believe at the same attributes that make the FPC molecule attractive and hemo dialysis setting has the potential to transform the way our deficiency is matters in arriving views.
These.
In a few moments, albeit dressing the leading opportunities for new therapeutic areas outside the dialysis study.
Underpinning our commitment to the hemodialysis community as our Dallas is concentrated business as a reminder, we're the number two suppliers as products in the U.S., which we generate more than 60 million annual revenue.
While triferic is clearly the growth and profit driver for our business going forward. The concentrates business allows us to develop at harvest relationships with key customers in the industry and is paving the way for discussions we're having with customers on triferic.
The other innovative part of our commitment to dialysis is triferic.
Only FD approved therapy in the U.S. indicated to replace iron and maintain hemoglobin in hemo dialysis patients during each dialysis treatment.
It has a unique and differentiated mechanism of action, which has the potential to benefit patients and the health care system.
Triferic delivers arent immediately and maintain hemoglobin in hemodialysis patients without increasing ferritin levels with the safety profile comparable to placebo and is not associated with iron overload and toxicity, we don't have to unique formulations of triferic better if the approved.
I've heard that I would say, which we launched it may 29 team and Triferic Avenue, our Ivy formulation, which we plan to launch in the fourth quarter of 2020.
Triferic out new enhancing for Triferic platform and that it provides patients with greater access to our interbedded therapeutic by expanding administrative options for clinicians and it is an excellent formulation for the development of new indications, we plan to introduce Triferic Avenue in the United States in the fourth quarter of 2020.
I'm proud of the way our company continues to respond to the cold with 19 pandemic.
The dialysis industry faces unique challenges because many patients are already carrying multiple comorbidities and patients lives are quite literally dependent on the treatment that they receive three times a week. Furthermore, one of the downstream impact to cope with 19 can be multiple organ failure, including kidney failure and this is put further threats.
Both acute and outpatient dialysis clinic.
At times like this are rolling supporting health care providers and patients is absolutely critical while we are still in the middle of the crisis and it's hard for us to predict the timing of when the world returns to a new normal I'm pleased to show that we've seen no disruption to our supply chain for either concentrate or triferic.
In addition, because of the fragile nature dialysis patients clinics have restricted access to facilities by not a central workers, including our sales representatives and nurse educators and they bought any significant change protocols.
Focus on managing the crisis. This has impacted our ability to continue the promotion of and medical education for Triferic, though we had been working to you our efforts virtually where possible.
However, in certain U.S. geography sort of started to slowly reopened.
We have taken careful steps to review in person clinic visit we're safe.
Subject to any further adverse development.
We're also closely evaluating the potential impact of the cobot 19 on outbreak across the globe on a regulatory clinical development timeline, particularly in China, India and on the commercialization timelines in Chile, where Triferic Dialysate was recently approved.
Finally, I'd like to applaud the efforts of all essential workers and goes on the front line working in dialysis clinics to ensure patients received their lifesaving therapy.
Particular, I'm proud of the extraordinary efforts of our manufacturing and distribution employees, who come to work every day, but make sure that we are following through on our commitment to the dialysis industry in patients and standing with the industry in the face of this crisis.
Now turning to some of the highlights of the second quarter.
Net sales were 15.9 million.
Derek net sales were point 2 million and point 5 million for three and six month ended June Thirtyth 2020.
For Triferic Dialysate, we ended the quarter with nearly 2800 patients on therapy, representing more than 400000 annualized treatment.
We sign contracts with 12 additional critics of 44% increase in contract clinics compared to Q1 2020.
An additional eight clinics affiliated with an embryo were trained and approved for adoption in Q2, and consequently, all clinics, we contracted during Q2 converted into.
Our active or committed evaluation program for Triferic dialysate represent 26 independent in small and medium balances organization clinic.
Jim will provide additional details on the launch metrics later in the call.
We made progress expanding the reach of our real World data program, adding additional clinics in the second quarter and we were thrilled to appoint Dr. Allen Mrs into our board of directors.
I wanted to write downs of already on kidney disease, and its clinical regulatory and public policy expertise combined with his senior executive experience at a large dialysis organization will make him a valuable advisor as we seek to expand reach and impact of Triferic.
Well into the second quarter saw two important regulatory milestone for Rockwell medical the acceptance of the new drugs submission of Triferic Avenue by Health, Canada, and the regulatory approval of Triferic fallacy in Chile.
That I'll hand, the call over to Tim coal to discuss commercial metrics and the Triferic have new launch with him.
Thanks Russell.
He was second quarter, we continue to make important progress in the commercialization of Triferic dialysate.
Despite the challenges of the Cobiz 19 pandemic.
So as Russell mentioned, we had nearly 2800 contracted patients on therapy at the end of June.
Representing more than 400000 annualized treatments.
The increase was attributable to the signing of commercial contracts with clinics that had started their 90 day evaluation programs in the first quarter.
We continued to see a high success rate with our no cost evaluation program approach.
As a majority of participants see positive results with triferic in their own patients and subsequently transition to paying customers.
And the second quarter, we signed 12, new contracts with dialysis clinics to adopt Triferic dialysis.
An additional eight clinics affiliated with an M.D.O. were trained.
Approved for adoption as of June Thirtyth 2020.
And substantially all clinics contracting within Q2 converted in June.
The overall growth in Triferic sales was lower than expected in the quarter.
I merely due to the restrictions dialysis clinics have levied on in person visits from field staff.
However, we are pleased with the results our sales and clinical nurse educator teams have produced by leveraging virtual engagement tactics to complete training programs and couples contracts.
Late in the quarter, we saw relaxing of restrictions in certain U.S. geography, which has allowed us to reengage with more clinics.
And get back on track with planned in person training programs.
The 12, new clinics, we added in the second quarter took our total number of clinics under contract up to 39.
26, Glenn its participated in evaluation programs during the quarter.
Decrease versus the previous true the decrease was directly due to a number of clinics delaying triferic evaluations, while they focused on managing through the code 90 crisis.
Evaluation programs have now been active for four full quarter since the product launch and allow clinics to sample triferic dialysate for three month period.
Our clear observation today is that a significant majority of the clinics to gain experience with triferic.
To stay with our product as evidenced by the study 75% conversion rate.
From a valuation programs to commercial contracts.
And while Cobot 19 has presented challenges to commercial companies throughout our industry, including our company.
We have equipped our field force with tools to continue to communicate virtually with customers until such time, when more U.S. geography has reopened allowing face to face visits.
We expect to see a rich reacceleration of adoption structured as the Colby Nike pandemic begins to resolve and more U.S. states reopen for business. This is particularly important for triferic.
And the evaluation sales process since a high touch.
Hi support hands on approach by our field personnel.
Yields the best results.
Next I'll turn to Triferic Avenue, or I'd be formulation of Triferic.
With the FDA approval of Triferic Avenue in March.
Triferic Avenue join Stryker dialysate as the only ft, a fruit products indicated to replace iron and maintain hemoglobin.
In adult patients with hemo dialysis dependent chronic kidney disease.
Drug Avenue is designed for intravenous administration.
Two adult hemodialysis patients and enhances the Triferic platform.
Hi, providing patients with greater access to our innovative therapeutic.
By expanding administration options for clinics.
The therapy allowed dialysis centers to administer track circuit patients regardless of the mode of bicarbonate delivery being used and thus is more appropriate in cases, where hemodialysis clinic is using a dry bicarbonate technology.
Regarding the launch plan for Triferic Avenue or outreach to prospective customers to increase the awareness. The impending launch started in the second quarter and is ongoing.
Currently this includes reaching out to customers, who have already expressed interest in triferic in the past what had been unable to adopt due to their use of dry bicarbonate technology.
We're also engaging with dialysis organizations that we have established contracts with for dry Triferic dialysate.
To set the stage for adding Triferic Avenue to those agreements so that their customers, who utilize dry bicarbonate systems can have access to triferic.
At same time, we're preparing integrated marketing communications and educational programs that we will launch to signal commercial availability of the product later this year.
In parallel we are manufacturing both sample and commercial products with the final FDA approved labeling branding.
Applying learnings from our launch of Triferic Dialysate, we expect you would initiate evaluation programs for prospective customers later in the third quarter in advance of the commercial launch.
Participating clinics will have access to free samples to treat patients and measure results.
During the evaluation period, we schedule regular lab reviews with the clinics to help them evaluate the impact structure, while also ensuring proper training and education in the clinic staff.
In parallel we will begin to negotiate commercial contracts with the clinics.
So that we are ready to onboard them is paying customers once devaluation is complete.
Accordingly, we plan to commence commercial sales of Triferic Avenue in the fourth quarter of 2020.
At the targeted clinics for early adoption reached completion point in their evaluation programs.
In terms of reimbursement, we continue to anticipate the Triferic Avenue will be reimbursed within the U.S. or do you bundle payment that has been established by CMS for Medicare patients and is increasingly prevalent for Medicaid patients.
But importantly, we believe the cost structure for Triferic Avenue enables us to make an attractive gross margin.
While still ensuring that this transformational therapy is broadly accessible to the patients who need a most.
We look forward to providing more detail on our commercial launch plans and progress in the coming months.
With that I'll turn the call back to Russell to provide an update on our real world data program.
Russell.
Thanks, Tim.
We expect the United States renal disease system or U.S. RDF.
To compare important measures of hospitalization and mortality in the center, we analyzed and presented on our last quarterly call.
Compared this with all other dialysis centers during the same time period.
Which was the first year that clinic use right very dialysate as part of a sample program in 2017.
As you can see from this five in that Senator hospitalizations per year at declined substantially.
Inpatient, Dave infectious hospitalization infectious inpatient, Dave and even debt while in all other U.S. dialysis centers taken together these parameters changed very little during this period, we have continued to add new centers to our real world data program and once inside of completed in your view.
We will start the analysis of Ivy our news hemoglobin and equally in addition, we have commenced an analysis of multiple clinic using the U.S. Rds database and expect to have these results towards the end of this year.
Now turning to our new indication as I mentioned earlier on the call I believed that there is potential for important value creation through the development of the PC platform for new indications outside of the hemo dialysis setting where there are significant need to transform the way our deficiency as manager.
In the past few months, we've been evaluating multiple potential opportunities for MPC platform to treat iron deficiency anemia in new indication.
Based on our analysis of factors, such as development consideration economics, and pricing and regimen ergonomic, we have identified two leading opportunity.
The top priority is FPC for patients receiving drugs or nutrients through at Ivy at home as we believe that this is an attractive market opportunity and the cost of the clinical program is likely to be relatively low.
<unk> area is experiencing substantial growth from 830000 patients in 20 tend to 3.2 million pesos in 29 team.
In a large subset of patients treated with home infusion the incidence of iron deficiency, and or iron deficiency anemia is estimated to be as high as 60%.
We estimate the market opportunity for MPC as a home infusion therapy to be greater than 600 million.
Currently iron requirements can only be met within in office Ivy art infusion business due to the hypersensitivity risk these products, whereas we believe FPC could be safely administered through an ivy at home.
We estimate that market access for FPC will be favorable largely because payers and want to reduce costs. The hospital office visits.
For the administration of these drugs or nutrients.
Approximately 50% of patients covered by commercial payers and Medicare coverage currently through a specific part b home infusion benefit.
We intend to have a type C meeting with FDA by the end of this year to discuss this program and pending this discussion. We currently estimate that phase two studies could be initiated in 2021 for a total cost of $1.5 million to $2.5 million and be completed in 13th month, while we estimate that the phase three.
The program could cost $5 million to $8 million and be completed and approximately two years.
The second priority under consideration is FTC to improve cardiac function in hospitalized acute congestive heart failure patients.
Studies with older forms of parental iron has consistently demonstrated meaningful benefit in heart failure patients in the outpatient setting.
However, with these products the release of our from the liver is likely to be too slow to produce a benefit in the hospital setting.
However, because FPC provides immediate bioavailability of iron it could improve cardiac function in hospitalized patients with a goal of reducing length of stay and or 30 day readmission and their associated clinical problem and crop.
We estimate that a phase two clinical proof of concept study examining and improvement in cardiac bio energetic function would enable a phase III program.
The Rockwell management team along with relevant thought leaders will hold a conference call on the 24th of September to provide more depth in detail on the new indication and their associated clinical program.
The call will include such details as the commercial potential with each new indication the rationale in Cleveland clinical feasibility and more detail on the clinical program.
We encourage you to join the call and will provide information on accessing the conference call and webcast in the near future.
With that I will turn it over to Paul Mcgarry for a review of our second quarter financial Paul.
Thanks Russell.
Turning now to our second quarter results are more fulsome description of all results can be accessed in both the press release, we issued this afternoon as well as our 10-Q filing for the quarter and I would encourage investors to read our detailed disclosures for a more complete understanding of our financial results.
I'd like to start by highlighting a strong liquidity position as we ended the second quarter.
We ended the quarter with cash cash equivalents and investments available for sale of 40 million compared to approximately 48.9 million a march 31st what each one.
Cash used in operating activities was 16.2 million six months ended June 30 2020.
Balance sheet restricted by the sale of 987760 chairs of our common stock through our at the market equity offerings facility for proceeds of 2 million net of issuance costs.
We have approximately 32.6 million remaining under this facility.
Turning to the income statement.
Net sales for the second quarter 2020 were 15.9 billion, an increase of 7.1% compared to net sales of 14.8 million the second quarter of 2018.
The increase was primarily due to the increased sales you know dialysis comps treats products trucks for net sales for the second quarter 2020 were approximately point 2 million compared to net sales of approximately 1 million the second quarter of 2019.
The increase was mainly due to a decrease in product sales.
International licensing fees remain constant.
Cost of sales for the second quarter 2020 was 15 million, resulting in a gross profit of point ninemillion compared to cost of sales for 2.1 billion in.
Gross profit of point 7 million during the second quarter of 29 cheap.
Gross profit increased 5.2 million in second quarter 2020, compared to the second quarter 2019.
Due primarily to an increase in sales word dialysis concentrate products offset by an increase in labor and material cost.
Sustain the increased demand, resulting from the ongoing cobot 19 pandemic.
Operating losses for the second quarter 2020 improved to 5.6 million from 10.4 million in the second quarter 2019.
The improvement in operating loss was driven primarily by a reduction in operating expenses expenses.
Which included 2.2 million reduction in selling and marketing expenses, a 2.6 million reduction Egina expenses 1.4 billion reduction in R&D expenses.
The decline in our sales and marketing expenses year over year is largely a result will be upfront investments we've made during the second quarter 2019.
To support the launch of trade for Dallas seats, and were partially offset by our continued investments in our sales and marketing infrastructure for Triferic.
The decline did you need expenses were driven primarily by a reduction in incentive compensation related to our former president and CEO.
Decline and legal costs associated with various litigation matters and have now been settled.
Lower consulting costs.
Finally, the decline in R&D expenses year over year are largely due to timing of certain costs and the upfront investments we made in our medical platform during the second quarter 2019th.
To support the development in the global launch expect FERC, which included investments, we've made and continue to make to enhance our medical platform and generate data to support a terrific and FPC platform, including the data we presented early on this call.
We expect a research and product development expenses to increase in the future due to additional clinical development of our FPC technology platform innovation to the administration of Triferic, the continuation of the pediatric clinical trial, and an increasing headcount to support medical education efforts for Triferic.
Most of the second quarter 2020.
6.9 million or 10 cents per basic and diluted share compared to net loss second quarter 2018 of 10.3 million or 18 cents per basic and diluted share.
The additional area that is important to our company going forward is international and business development activities for Triferic.
A significant objective for the company is to increase access to trucker in international markets.
Yes, we do this we see an opportunity to create value for our shareholders.
Certainly we believe the were real world data that we are generating for Triferic has the potential to help us accelerate some of the business development discussions we're having around the globe.
Earlier this year, we entered into exclusive licensing supply agreements with some farmer so the rights to commercialize triferic in India.
India has a potentially attractive market from trade for over 120000 hemo dialysis patients.
Second quarter immediate between Sun pharma and the regulatory authorities in India have been initiated.
Some form of continues to follow the India regulatory authorities to determine a pathway to regulatory.
In China.
We're working diligently with our partner long been buyer parcels.
To initiate a trial for transfer to support the filing for regulatory approval.
We expect that this study will be initiated later this year.
Access to hemo dialysis in China has continued to increase at a rapid rate in recent years.
Over 600000 hemodialysis patients in China, making is the largest single market in the world.
We remain excited about potential for Triferic in China, and we expect to participate meaningfully in the commercial opportunity. If triferic is approved we constructed royalty in the low to mid 20% range of product sales.
We filed our new drugs submission for Triferic Avenue in Canada, which tells counted accepted in May and anticipate regulatory decision late Q2.
Early Q3 2021.
In South America received.
Regulatory approval for trucker dialysate in Chile, and are progressing towards commercial launch of Triferic Triferic dialysate in Peru distribution partner there.
Both of these markets, we receive a transfer price centric Berg sold to the distributor.
We were also continuing discussions relating to refer to other geographies, such as Europe and Japan.
We expect to leverage some of the real world data that is presented on this call and our Q1 2020 earnings call in discussions with respect to partners to highlight potential formal pharmaco economic and health economic benefits that may be observed Patrick Burke.
We believe that both of these markets will require clinical studies for triferic to facilitate regulatory approval and accordingly, the due diligence and discussions we are how big are inherently more complex in some of the markets, where we are already partner.
Now I'll turn the call back to Russell.
Thank you Paul.
With that I would like to open up the call to others to ask questions operator.
Certainly ladies and gentlemen, if you have a question at this time. Please press Star then one on your Touchtone telephone. If your question has been answered and you'd like to move yourself from the Q. Please press the pound key and our first question comes from the line up Ram tells us from H.C. Wainwright. Your question. Please.
Hi, This is Blair calling on for ROM couple of questions for me can you give us in a bit an update on how the early stage commercial efforts are progressing for Avenue, what is the reception been light.
Reception been like from the initial customer outreach and how many evaluation programs are you targeting for third quarter.
Thanks, Ron Tim I think you can best are quite a bit.
Yes. Thank you for the question.
So we actually have just started the evaluation programs I'm here in the third quarter for Triferic Avenue.
Again, we had to wait until we had ramped up a sample inventory enough to support those programs will officially launched then.
In September initial response has been good customers that have expressed interest in triferic in a password decided to see that this new I'd be formulation is coming.
So we expect to be some enthusiasm amongst those customers and early indication is that that.
There will be many customers interested in starting evaluations as soon as the products available.
Hi, and we are targeting and minimum of 100 sites for evaluation programs before the end of the year and.
As a goal for us, but we certainly are excited about the product and have had good responses to date.
Okay, Great and if you could just provide an update on partnership discussions in Europe, Japan and Korea. That's it for me. Thank you.
Yeah, I'll pick up so.
In Europe, where.
Engaged in partnership discussions, particularly supported by our real World data.
And the same goes for Korea.
And.
The same also goes for Japan and in Japan. The key issue is of course pricing because of the pricing regime there but.
Discussions are active in ongoing in those markets.
Thank you.
Thank you aren't next question comes in a line of branded folks from Cantor Fitzgerald. Your question. Please.
Hi, Thanks for taking my question and congratulations on all the program in Nicole and sort of a two part question.
Can you just elaborate and the drivers of patient growth in the quarter on this to be very impressive. So just where are these small midsize a large facilities and then well what's this patient growth driven by new facilities facilities that are already contracted with in the Pos and actually saw increased usage within those facilities.
And then secondly, the second part of my question is just how long does it take from.
The signed contracts.
Until sort of it can vary of significant revenue poetry is it as the evaluation program and they convert the whole clinical how should we think about that's sort of ramp up to a solid run rate for these clinics.
You saw this contract thank you.
The great question Tim.
Yes. Thank you for the question so.
To your first question.
When clinics finished the evaluation program and transfer over to purchasing customers on contract there ready right away to have all patients in the clinic on Triferic dialysate at one time, so there really isn't a ramp up period with that product because the products mixed in the central loop in all patients that are on the central loop.
Received received a product so that's a nice feature of Triferic dialysate is that there isn't a ramp up once the evaluation has done a contract to sign and the customers purchasing so really the growth that we've had.
In patients in sort of our new milestone of 400000 annualized contract at treatments is due to new clinics coming on board and the majority of those that were in the second quarter. We're pointing out that had finished the evaluation period that they started in the first quarter. So hopefully that gives you a sense of how that growth occurs in <unk>.
Correct again, a high rate of conversion for the evaluation programs that we have ongoing today.
Great. Thank you.
Thank you. This does conclude the question and answer session of today's program I'd like to hand, the program back to Dr. Allison for any further remarks.
Well. Thank you all very much for participating in this quarterly call I appreciate your attention and your support.
And we look forward to communicating with you.
Again, thank so much.
Thank you ladies and gentlemen few participation at today's conference. This does conclude the program you may now disconnect good day.
Yeah.
[music].